FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1565236259> ?p ?o ?g. }

• W1565236259 endingPage "E208" @default.
• W1565236259 startingPage "E203" @default.
• W1565236259 abstract "Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? In bladder-sparing approach incorporating TURBT and chemoradiotherapy (CRT) to MIBC, patients who clinically achieve complete response to induction CRT enjoy favourable prognosis and quality of life with preserved functioning bladder, whereas those with persisting disease have poor prognosis despite salvage radical cystectomy. Risk factors for cancer death among the non-responders remain fully unknown. The current study showed that survival of the non-responders is clearly stratified into low- and high-risk groups based on pathology of cystectomy specimens; 5-yr CSS rates for low- (pTO-2pNO) and high-risk (pT3-4a or pN+) patients were 85% and 20%, respectively. OBJECTIVE • To stratify patients with a clinical non-complete response (CR) after induction chemoradiotherapy (CRT) according to their risk of death from cancer, based on pathology of cystectomy specimens. PATIENTS AND METHODS • From 1997 to 2009, 170 patients with cT2-4aN0M0 bladder cancer underwent transurethral resection followed by induction CRT (40 Gy with cisplatin). Clinical response was evaluated 4–6 weeks after completion of CRT. • Patients who met partial cystectomy (PC) criteria underwent PC plus pelvic lymph node dissection for bladder preservation. Otherwise, radical cystectomy (RC) was recommended. • PC criteria were unifocal tumours, intact bladder neck and trigone, and CR (defined as no evidence of residual disease) or minimal amounts of residual non-muscle-invasive bladder cancer after induction CRT. • Pathological variables associated with cancer death were analysed in patients who underwent PC or RC using a multivariate Cox proportional hazard model. RESULTS • Of 170 patients, 81 (48%) achieved a CR and 62 (36%) met the PC criteria. After CRT, 122 patients (72%) ultimately underwent PC (n= 44, 26%) or RC (n= 78, 46%). • The 5-year cancer-specific survival (CSS) rate was 96% for the patients with a CR and 50% for patients with non-CR (P < 0.001, median follow-up for survivors: 48 months). • In the 122 patients who underwent cystectomy, pT3-4a (hazard ratio [HR] 8.3 versus pTO-2, P < 0.001) and pN+ (HR 3.0 versus pNO, P = 0.037) were identified as significant and independent risk factors among variables including pT stage, lymph node yield at cystectomy, pN stage, and Iymphovascular invasion. A similar result was obtained through analysis of a sub-cohort of 69 patients with non-CR. • Patients with non-CR were stratified according to their risk factors into low- (pT0-2pN0, 5-year CSS rate 85%) and high-risk (pT3-4a or pN+, 5-year CSS rate 20%) groups. CONCLUSION • In CRT-based bladder-sparing approaches, patients with a clinical non-CR after induction CRT can be stratified into low- and high-risk groups for death from cancer based on pathology of cystectomy specimens. Patients at high risk are potential candidates for intensive adjuvant therapy including clinical trials." @default.
• W1565236259 created "2016-06-24" @default.
• W1565236259 creator A5001139671 @default.
• W1565236259 creator A5006217384 @default.
• W1565236259 creator A5015291340 @default.
• W1565236259 creator A5030126202 @default.
• W1565236259 creator A5031050928 @default.
• W1565236259 creator A5048350768 @default.
• W1565236259 creator A5081085839 @default.
• W1565236259 creator A5088037725 @default.
• W1565236259 creator A5089503656 @default.
• W1565236259 date "2012-01-30" @default.
• W1565236259 modified "2023-10-16" @default.
• W1565236259 title "Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches" @default.
• W1565236259 cites W1902718972 @default.
• W1565236259 cites W1952252771 @default.
• W1565236259 cites W1985950314 @default.
• W1565236259 cites W2005530757 @default.
• W1565236259 cites W2017629237 @default.
• W1565236259 cites W2028936192 @default.
• W1565236259 cites W2033511033 @default.
• W1565236259 cites W2049695002 @default.
• W1565236259 cites W2063738425 @default.
• W1565236259 cites W2070035041 @default.
• W1565236259 cites W2072167013 @default.
• W1565236259 cites W2086141729 @default.
• W1565236259 cites W2102534146 @default.
• W1565236259 cites W2113156769 @default.
• W1565236259 cites W2116331814 @default.
• W1565236259 cites W2124971024 @default.
• W1565236259 cites W2129035327 @default.
• W1565236259 cites W2130962341 @default.
• W1565236259 cites W2138798550 @default.
• W1565236259 cites W2144356064 @default.
• W1565236259 cites W2153157914 @default.
• W1565236259 cites W2157020021 @default.
• W1565236259 cites W2171237326 @default.
• W1565236259 cites W2329076941 @default.
• W1565236259 doi "https://doi.org/10.1111/j.1464-410x.2011.10874.x" @default.
• W1565236259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22289431" @default.
• W1565236259 hasPublicationYear "2012" @default.
• W1565236259 type Work @default.
• W1565236259 sameAs 1565236259 @default.
• W1565236259 citedByCount "11" @default.
• W1565236259 countsByYear W15652362592012 @default.
• W1565236259 countsByYear W15652362592013 @default.
• W1565236259 countsByYear W15652362592014 @default.
• W1565236259 countsByYear W15652362592015 @default.
• W1565236259 countsByYear W15652362592019 @default.
• W1565236259 countsByYear W15652362592020 @default.
• W1565236259 countsByYear W15652362592021 @default.
• W1565236259 countsByYear W15652362592023 @default.
• W1565236259 crossrefType "journal-article" @default.
• W1565236259 hasAuthorship W1565236259A5001139671 @default.
• W1565236259 hasAuthorship W1565236259A5006217384 @default.
• W1565236259 hasAuthorship W1565236259A5015291340 @default.
• W1565236259 hasAuthorship W1565236259A5030126202 @default.
• W1565236259 hasAuthorship W1565236259A5031050928 @default.
• W1565236259 hasAuthorship W1565236259A5048350768 @default.
• W1565236259 hasAuthorship W1565236259A5081085839 @default.
• W1565236259 hasAuthorship W1565236259A5088037725 @default.
• W1565236259 hasAuthorship W1565236259A5089503656 @default.
• W1565236259 hasBestOaLocation W15652362591 @default.
• W1565236259 hasConcept C121608353 @default.
• W1565236259 hasConcept C126322002 @default.
• W1565236259 hasConcept C126894567 @default.
• W1565236259 hasConcept C141071460 @default.
• W1565236259 hasConcept C143998085 @default.
• W1565236259 hasConcept C2775910329 @default.
• W1565236259 hasConcept C2778424827 @default.
• W1565236259 hasConcept C2780352672 @default.
• W1565236259 hasConcept C71924100 @default.
• W1565236259 hasConceptScore W1565236259C121608353 @default.
• W1565236259 hasConceptScore W1565236259C126322002 @default.
• W1565236259 hasConceptScore W1565236259C126894567 @default.
• W1565236259 hasConceptScore W1565236259C141071460 @default.
• W1565236259 hasConceptScore W1565236259C143998085 @default.
• W1565236259 hasConceptScore W1565236259C2775910329 @default.
• W1565236259 hasConceptScore W1565236259C2778424827 @default.
• W1565236259 hasConceptScore W1565236259C2780352672 @default.
• W1565236259 hasConceptScore W1565236259C71924100 @default.
• W1565236259 hasIssue "6b" @default.
• W1565236259 hasLocation W15652362591 @default.
• W1565236259 hasLocation W15652362592 @default.
• W1565236259 hasOpenAccess W1565236259 @default.
• W1565236259 hasPrimaryLocation W15652362591 @default.
• W1565236259 hasRelatedWork W2109785281 @default.
• W1565236259 hasRelatedWork W2189722039 @default.
• W1565236259 hasRelatedWork W2383341741 @default.
• W1565236259 hasRelatedWork W2595618663 @default.
• W1565236259 hasRelatedWork W2899655305 @default.
• W1565236259 hasRelatedWork W2904128870 @default.
• W1565236259 hasRelatedWork W2981737993 @default.
• W1565236259 hasRelatedWork W3027336582 @default.
• W1565236259 hasRelatedWork W3127820018 @default.
• W1565236259 hasRelatedWork W3128330365 @default.
• W1565236259 hasVolume "110" @default.
• W1565236259 isParatext "false" @default.

• next